Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/hgsi) is investigating potential claims against the board of directors of Human Genome Sciences Inc. (“Human Genome” or the “Company”) (NASDAQ: HGSI) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Human Genome to GlaxoSmithKline plc in a transaction valued at approximately $3 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Human Genome. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at firstname.lastname@example.org or visit: www.rmclasslaw.com/cases/hgsi.
Under the terms of the transaction, Human Genome shareholders will receive $14.25 per share of Human Genome stock they own.
If you own shares of Human Genome and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/hgsi. You may also email Mr. Maniskas at email@example.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.